Registration is officially OPEN for the 2024 DTRF Together We Will Weekend and RFA Walk. - Register Now

The Desmoid Tumor Research Foundation

July 2018

Doxorubicin-Eluting Intra-arterial Therapy for Pediatric Extra-Abdominal Desmoid Fibromatoses: A Promising Approach for a Perplexing Disease

Author Information

Elnekave E(1), Atar E(2), Amar S(3), Bruckheimer E(4), Knizhnik M(5), Yaniv I(3), Dujovny T(6), Feinmesser M(7), Ash S(3).

(1)Dept of Diagnostic Radiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel; Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. (2)Dept of Diagnostic Radiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. (3)The Rina Zaizov Hematology-Oncology Division, Schneider Children's Medical Center of Israel, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. (4)Section of Pediatric Cardiology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. (5)Dept of Diagnostic Radiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel. (6)Pediatric Oncology Unit, Emek Medical Center, Afula, Israel. (7)Dept of Pathology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Publication

J Vasc Intver Radiol

Summary

FULL ARTICLE HERE. Systemic doxorubicin is effective for desmoid fibromatosis (DF), but its use is limited by dose-dependent cardiotoxicity. A protocol of selective intra-arterial doxorubicin drug-eluting embolization (DEE) was designed to maximize target tissue efficacy of doxorubicin, while minimizing systemic exposure. Four children with recurrent or refractory DF were treated between 2014 and 2017. Tumor volumes were reduced by 54%–97% over a follow-up interval of 6–32 months. A single patient experienced transient lower extremity paresthesia (Common Terminology Criteria for Adverse Events grade I). Further investigation is needed to better establish these promising results for doxorubicin DEE in DF treatment.  

View Abstract